Pozen (NASDAQ:POZN) CEO John Platchetka likens the drug partnering process to a relay race. One runner at full speed finishes and hands the baton to another runner at full speed to finish the race. That’s the ideal. But in many cases, Big Pharma isn’t yet running when it receives the baton. Pozen developed migraine treatment […]
The initial public offering Cempra Pharmaceuticals plans now has a price. The Chapel Hill, North Carolina drug development company, which has two clinical-stage antibacterial compounds targeting drug-resistant bacteria, expects to sell 6 million shares for between $11 and $13 per share, raising up to $78 million before fees and expenses, according to an updated registration […]
Yusuf Qasim, President of Payments Optimization at Zelis, discussed how the company is transforming healthcare payments from a fragmented, patchwork system into a modern, digital infrastructure.
Vaccine technology company Heat Biologics has come into more money to help pay for clinical trials for its novel cancer-fighting immunotherapy. The North Carolina Biotechnology Center awarded the biotechnology company a $250,000 loan to cover some of the company’s trial expenses. Chapel Hill, North Carolina-based Heat is in the midst of a fundraising round expected […]
Heat Biologics, already in phase 2 clinical trials with an experimental treatment for nonsmall cell lung cancer, is readying to study its immunotherapy technology in additional cancers. The Chapel Hill, North Carolina company is more than halfway through a $4.1 million fundraising round to help that effort. Securities filings show that Heat Biologics has raised […]
The new cardiovascular drug being developed by Pozen (NASDAQ:POZN) does not yet even have a name, but it now has a manufacturer to produce it once it secures U.S. Food and Drug Administration approval. The Chapel Hill, North Carolina pharmaceutical company has reached a supply agreement with contract drug manufacturer Patheon (TSX:PTI), according to securities […]
A University of North Carolina at Chapel Hill genomics effort aimed at finding ways to turn the avalanche of genetic data into applications for patients has been awarded a $6.4 million federal grant. The grant, spread over four years, will establish the North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing, or NCGENES. Dr. James […]
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
To understand why Pozen (NASDAQ:POZN) sold future U.S. royalty rights for migraine drug Treximet, its lead revenue-generating product, it helps to understand what the company is doing with its drug pipeline right now. Chapel Hill, North Carolina-based Pozen has been directing resources to its PA drug platform, chiefly drug candidate PA32540, which is in phase […]
Pozen (NASDAQ:POZN) has sold the U.S. royalty rights for migraine drug Treximet to Canada’s national pension fund, CPPIB Credit Investments in a $75 million deal. The terms of the deal give the Chapel Hill, North Carolina pharmaceutical company a 20 percent interest in any royalties received by the pension fund starting April 1, 2018, according to […]
Topical nonsteroidal anti-inflammatory drugs have been limited by the difficulty of getting an active ingredient to effectively penetrate the skin. Chapel Hill, North Carolina pharmaceutical company Exodos Life Sciences aims to break that barrier with its drug candidate, ELS115. The company is raising money to help the effort. Exodos raised $1 million from an offering […]
If you only looked at Pozen‘s (NASDAQ:POZN) top and bottom lines from its third-quarter earnings, you might have missed a key detail affecting the pharmaceutical company’s financial performance. Although Chapel Hill, North Carolina-based Pozen’s revenue grew and its loss narrowed in the third quarter, the company insists results should be better and management pins those […]
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Millions of people use a 510(k) cleared medical device daily without even realizing the product has been evaluated by the Food and Drug Administration. It’s the toothbrush. The toothbrush is a a class I medical device, said Tammy Carrea, vice president quality and regulatory affairs for Durham, North Carolina medical technology company TransEnterix. Carrea uses […]
Regenerative medicine company Advanced BioHealing is now part of Shire (NASDAQ:SHPGY), but before it was acquired last May, the Westport, Connecticut company was hours from pulling the trigger on an initial public stock offering. ABH’s wound healing product for diabetics had made the company profitable in less than three years, but it needed more cash. […]
A long-running arthritis study at the University of North Carolina at Chapel Hill has been awarded a $3.25 million grant from the Centers for Disease Control and Prevention to follow up on patients first studied 20 years ago. More than 3,200 men and women from rural Johnston County, North Carolina are participating in the Johnston […]
Drug development company Cempra Pharmaceuticals plans to raise $86.2 million in an initial public offering to pay for late-stage clinical trials on a pair of novel antibiotic compounds targeting drug-resistant bacteria. The IPO filing comes a month after Chapel Hill, North Carolina-based Cempra announced positive phase 2 results for antibiotic candidate CEM-101, also called Solithromycin, […]
Digital drug marketing has been pharmaceutical company Pozen‘s (NASDAQ:POZN) mantra for much of this year. The Chapel Hill, North Carolina-based company has made clear that when it goes to market with its new cardiovascular drug, a digital strategy will dictate its reach to patients and physicians in ways that traditional pharmaceutical sales representatives have not […]